Skip Navigation LinksHome > January 2014 - Volume 133 - Issue 1 > PIK3CA Activating Mutations in Facial Infiltrating Lipomatos...
Plastic & Reconstructive Surgery:
doi: 10.1097/01.prs.0000436822.26709.7c
Experimental: Original Articles

PIK3CA Activating Mutations in Facial Infiltrating Lipomatosis

Maclellan, Reid A. M.D., M.M.Sc.; Luks, Valerie L. B.S.; Vivero, Matthew P. B.A.; Mulliken, John B. M.D.; Zurakowski, David Ph.D.; Padwa, Bonnie L. D.M.D., M.D.; Warman, Matthew L. M.D.; Greene, Arin K. M.D., M.M.Sc.; Kurek, Kyle C. M.D., M.M.Sc.

Collapse Box

Abstract

Background: Facial infiltrating lipomatosis is a nonheritable disorder characterized by hemifacial soft-tissue and skeletal overgrowth, precocious dental development, macrodontia, hemimacroglossia, and mucosal neuromas. The authors tested the hypothesis that this condition is caused by a somatic mutation in the phosphatidylinositide-3 kinase (PI3K) signaling pathway, which has been indicted in other anomalies with overgrowth.

Methods: The authors extracted DNA from abnormal tissue in six individuals, generated sequencing libraries, enriched the libraries for 26 genes involved in the PI3K pathway, and designed and applied a sequential filtering strategy to analyze the sequence data for mosaic mutations.

Results: Unfiltered sequence data contained variant reads affecting ~12 percent of basepairs in the targeted genes. Filtering reduced the fraction of targeted basepairs containing variant reads to ~0.008 percent, allowing the authors to identify causal missense mutations in PIK3CA (p.E453K, p.E542K, p.H1047R, or p.H1047L) in each affected tissue sample.

Conclusions: Affected tissue from individuals with facial infiltrating lipomatosis contains PIK3CA mutations that have previously been reported in cancers and in affected tissue from other nonheritable, overgrowth disorders, including congenital lipomatous overgrowth, vascular, epidermal, and skeletal anomalies syndrome, Klippel-Trenaunay syndrome, hemimegalencephaly, fibroadipose overgrowth, and macrodactyly. Because PIK3CA encodes a catalytic subunit of PI3K, and in vitro studies have shown that the overgrowth-associated mutations increase this enzyme’s activity, PI3K inhibitors currently in clinical trials for patients with cancer may have a therapeutic role in patients with facial infiltrating lipomatosis. The strategy used to identify somatic mutations in patients with facial infiltrating lipomatosis is applicable to other somatic mosaic disorders that have allelic heterogeneity.

©2014American Society of Plastic Surgeons

Login

Article Tools

Share


The Clinical Masters of PRS – Breast eBooks
4 Essential eBooks for Plastic Surgeons